+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

OKT3 and viral disease in pediatric liver transplant recipients



OKT3 and viral disease in pediatric liver transplant recipients



Clinical Transplantation 5(4): 294-300



Seventy-four consecutive pediatric liver transplant recipients were reviewed to assess the effect of the monoclonal anti-T-lymphocyte antibody OKT3 on subsequent viral infection (9 patients were excluded due to postoperative demise during the 1st week). Twenty-two patients received OKT3 in addition to standard cyclosporine-prednisone immunosuppression for either steroid-resistant acute rejection (18) or to facilitate reduction of cyclosporine due to severe renal impairment (4). Invasive infections were diagnosed by histology or culture in tissue biopsies or bronchoalveolar lavage specimens. The overall incidence of viral infection was 58%, half of which was due to cytomegalovirus (CMV). Invasive viral disease was associated with increased mortality (37% vs. 3% p = 0.001). Viral-related deaths were due to CMV (5), disseminated adenovirus (3), disseminated enterovirus (1) and respiratory syncytial viral pneumonia (1). The use of OKT3 was associated with increased viral disease (59% vs. 33% p=0.04) and invasive primary CMV disease (58% vs. 19% p=0.04). Trends were observed toward increased overall viral infection (73% vs. 51 % p=0.08), primary CMV infection (58% vs. 25% p=0.08) and overall mortality (27% vs. 9% p =0.08) following OKT3 therapy. We conclude that pediatric liver transplant recipients who require OKT3 therapy may be at increased risk for invasive viral disease and especially invasive primary CMV disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 054696988

Download citation: RISBibTeXText

PMID: 21170278


Related references

Use of orthoclone okt3 in pediatric liver allograft transplant recipients. Pediatric Research 23(4 Part 2): 312A, 1988

OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients. Transplantation Proceedings 26(1): 154-156, 1994

Induction therapy with OKT3 in pediatric liver-transplant recipients. Transplantation Science 4(Suppl. 1): S20-S25, 1994

OKT3 treatment of steroid-resistant rejection in pediatric liver transplant recipients. Journal of Pediatric Gastroenterology and Nutrition 14(1): 86-91, 1992

Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplantation Proceedings 23(1 Pt 2): 1473-1476, 1991

Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 66(12): 1641-1644, 1998

Ganciclovir Prophylaxis Reduces the Incidence and Severity of Cytomegalovirus Disease in Seropositive Liver Transplant Recipients Treated with OKT3. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33: 403, 1993

OKT3 induction in pediatric renal transplant recipients. Pediatric Nephrology 6(5): C143, 1992

Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 60(11): 1357-1360, 1995

The use of interferon for the treatment of viral hepatitis in pediatric liver transplant recipients. Journal of the Oklahoma State Medical Association 88(9): 406-407, 1995

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrobial Agents and ChemoTherapy 37(11): 2490-2492, 1993

Monoclonal antibody OKT3 therapy in pediatric kidney transplant recipients. Journal of Pediatrics 116(5): S86-S91, 1990

Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma. Pediatric Transplantation 8(3): 243-248, 2004

Prevention and treatment of selected fungal and viral infections in pediatric liver transplant recipients. Clinical Transplantation 5(2 part 2): 204-207, 1991

Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transplantation 19(7): 730-740, 2013